Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts. Show more

Location: 830 Winter Street, Waltham, MA, 02451, United States | Website: https://www.q32bio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

32.45M

52 Wk Range

$1.34 - $53.79

Previous Close

$3.32

Open

$2.54

Volume

4,025,424

Day Range

$2.51 - $3.08

Enterprise Value

-28.51M

Cash

65.48M

Avg Qtr Burn

-16.41M

Insider Ownership

6.57%

Institutional Own.

73.27%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.